Press Release
Nokia Defense and C3IA partner to accelerate digital transformation across UK defense operations

  • Partnership combines Nokia Defense’s advanced connectivity with C3IA’s systems engineering, capability integration and security services expertise to support UK defense modernization.
  • Focuses on delivering resilient multi-domain capabilities spanning tactical communications, C2, sensing, autonomous systems and edge computing.
  • Builds on Nokia Defense and C3IA’s participation in the UK MOD TacSys framework to enhance tactical communications and interoperability.

16 September 2026
Espoo, Finland – At the 2026 DVD (Defence Vehicle Dynamics) event, Nokia Defense and C3IA, a UK specialist in systems engineering, capability integration and security services, announced the signing of a memorandum of understanding (MoU) to strengthen collaboration and support the digital transformation of UK Defense. The partnership combines Nokia’s expertise in advanced connectivity with C3IA’s engineering, capability integration, support and security services to help deliver next-generation defense capabilities for modern, multi-domain operations.

Together, the companies will deliver resilient communications, secure information sharing and network interoperability across land, air, maritime, cyber and space domains. The collaboration also builds on Nokia Defense and C3IA’s participation in the UK Ministry of Defence (MOD) Tactical Communication Systems (TacSys) framework, providing access to Nokia’s full connectivity portfolio from headquarters to the tactical edge.

Modern military operations increasingly depend on the ability to securely connect people, platforms, sensors and data across multiple domains. Under the agreement, Nokia Defense and C3IA will co-develop solutions across tactical and operational communications, private 4G and 5G, situational awareness, command and control (C2), sensing, autonomous systems and edge computing. The collaboration will focus on translating advanced communications technologies into practical, integrated capabilities that address real operational requirements for the defense sector.

“Through this collaboration with C3IA, we are combining resilient, mission-critical connectivity with expertise in defense systems engineering and support services to help turn technology into operational capability and advance tactical communications and interoperability across future UK defense programs,” said Mikko Viitaniemi, Vice President and Head of Nokia Defense.

“Delivering defense capability at pace requires more than technology alone. It requires the right combination of secure communications, sector expertise and systems integration. Our partnership with Nokia enables the rapid deployment of innovative capabilities that can deliver real operational value on the battlefield. Ultimately, our shared goal is to connect the battlespace, strengthen national security, and help equip the MOD for the future,” said Steve Brown, Managing Director, C3IA.

Nokia Defense and C3IA participate in the UK Government’s TacSys framework (RM6393) in Lot 1 (Services) and Lot 3 (Components), giving the UK MOD and other public sector organizations the ability to procure Nokia’s connectivity portfolio to support future tactical communications requirements.

Nokia Defense provides secure, intelligent connectivity for defense in the AI era. Built on Nokia’s global leadership across fixed, mobile, and transport networks, it delivers resilient, mission-ready communications solutions that strengthen national security and support critical operations worldwide.

Multimedia, technical information and related news
Web Page: www.nokia.com/defense-communications
Web Page: www.c3ia.co.uk

About Nokia
Nokia is the world’s leading provider of network technology and enables a new era of artificial intelligence. We are developing the networks of the future that connect people, devices and intelligence. Our network solutions span fixed and mobile networks, as well as IP, optical, core, and data center networks. Our secure, AI-native network infrastructure enables the application and utilization of AI on a global scale.

About C3IA
C3IA provides technical and security services across both public and private sectors. Specialising in systems engineering, ICT, information assurance, and NCSC-assured cyber services, C3IA plays a pivotal role in supporting the delivery of critical defence programmes. C3IA is dedicated to building long-lasting relationships with our clients, partners and community, delivering exceptional value through our commitment to quality and collaboration.

Media inquiries
Nokia Press Office
Email: Press.Services@nokia.com

Follow us on social media
LinkedIn X Instagram Facebook YouTube

  • New data will highlight the breadth of semaglutide evidence across the cardiometabolic spectrum, including obesity, type 2 diabetes, cardiovascular, kidney and fatty liver disease, and new data on Wegovy® pill, Wegovy® 7.2 mg and Ozempic® 2.0 mg
  • Real-world evidence from the OCTANE study will provide insights into Wegovy® pill use in adults with overweight or obesity, including weight outcomes, treatment switching and patient-reported outcomes
  • CagriSema and amylin-based pipeline data will provide new insights into appetite regulation, eating behaviour, food noise, body composition and bone health (bone remodelling mechanisms). The data will advance our understanding of the underlying biology of obesity and type 2 diabetes and inform next-generation cardiometabolic innovation.

Bagsværd, Denmark, 16 September 2026 – Novo Nordisk today announced that new data from its cardiometabolic pipeline and portfolio will be presented at the upcoming 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2026 in Milan, Italy, from 28 September to 2 October. The data to be presented at EASD will bring new scientific insights shared across obesity, type 2 diabetes, cardiovascular, kidney and liver-related outcomes. Together, the presentations reflect Novo’s continued focus on advancing understanding and treatment of interconnected cardiometabolic diseases to help many more patients.

A total of 44 abstracts will be presented, including data across semaglutide, CagriSema, and zenagamtide. Key presentations will include real-world evidence on Wegovy® pill and CagriSema data exploring appetite regulation, eating behaviour and brain responses to food cues using fMRI (functional Magnetic Resonance Imaging; a non-invasive brain scan that shows which areas of the brain are active during specific tasks or while at rest), and CagriSema data in type 2 diabetes looking at body composition, organ-level fat and bone remodelling mechanisms. Additional presentations include data on semaglutide addressing excess liver fat in people with obesity, and real-world evidence comparing major adverse cardiovascular events in adults with type 2 diabetes escalating to semaglutide 2.0 mg versus switching to tirzepatide.

“At EASD 2026 we are sharing the breadth and progression of our cardiometabolic portfolio and pipeline, including key insights that show how our science could make a difference in the everyday lives of people living with obesity, diabetes and related diseases,” said Martin Holst Lange, executive vice president of Research & Development and chief scientific officer at Novo. “We are presenting real-world data on Wegovy® pill, new insights into the broader benefits of semaglutide across Wegovy® and Ozempic®, and CagriSema research exploring food noise, brain responses and body composition. Together, these findings have the potential to shape the next generation of cardiometabolic care and reflect our ambition to develop treatments that can help us work towards more meaningful outcomes for patients.”

Media are invited to listen to an International Press Briefing on Wednesday, 30 September 2026, during EASD in Milan. The event will be accessible via a webcast on the Novo website, sign up via this link: Novo Nordisk: EASD International Press Briefing, 30 September 2026 (Virtual only)

Summary of presentations
Accepted data at the 62nd Annual Meeting of the EASD include the following oral presentations and short oral discussions. Accepted abstracts include preliminary data that may be subject to change in the final published manuscripts. Dates and times of the presentations can be found on the EASD website.

Select Novo abstracts to be presented at EASD’s 2026 Scientific Sessions:

EASD Scientific symposium:

  • REIMAGINE 1,2 and 3 Trial: Trial designs, key results and clinical perspectives: Scientific Session presentation (S21: Amylin in diabetes and obesity: What’s new?) – Wednesday 30 September; 16:30 – 17:30 CEST

Novo oral presentations and short oral discussions:

CagriSema (diabetes and obesity)

  • Efficacy of CagriSema on body composition in participants with early type 2 diabetes: REIMAGINE 1. Oral presentation (LBA 11) – Tuesday 29 September; 14:45–16:15 CEST
  • Effect of CagriSema on achievement of composite HbA1c and weight reduction targets in participants with type 2 diabetes: REIMAGINE 1. Oral presentation (LBA 12) – Tuesday 29 September; 14:45–16:15 CEST
  • fMRI – Effects of CagriSema on appetite, eating behaviour and food cue reactivity using functional MRI in adults with overweight or obesity. Oral presentation (122) – Wednesday 30 September; 14:30–16:00 CEST

Cagrilintide

  • Impact of cagrilintide 2.4 mg on physical function: post-hoc patient-reported outcomes from REDEFINE 1. Short oral discussion (593) – Tuesday 29 September; 12:00–13:00 CEST

Zenagamtide (diabetes)

  • Zenagamtide (amycretin), a novel unimolecular GLP-1 and amylin receptor agonist: phase 2b results in type 2 diabetes. Oral presentation (13) – Wednesday 30 September; 9:45–11:15 CEST

Wegovy® (injection and tablets)

  • OCTANE RWE US study: 3-month real-world weight outcomes among patients with overweight or obesity after switching from injectable semaglutide or tirzepatide to oral semaglutide for weight management. Short oral discussion (LBA 59) – Wednesday 30 September; 11:45–12:45 CEST
  • Effect of semaglutide on liver measures and indices: pooled analysis from the STEP UP studies. Short oral discussion (529) – Thursday 1 October; 12:45–13:45 CEST

Ozempic®

  • COMPETE SWITCH CV: Major adverse cardiovascular events in adults with type 2 diabetes escalating to semaglutide 2.0 mg vs switching to tirzepatide: Short oral discussion (LBA 44) – Tuesday 29 September; 12:00–13:00 CEST
  • Sema 2.0-7.2 bridging: Pharmacometric modelling of escalating to subcutaneous semaglutide once-weekly 7.2 mg from 2.0 mg in a STEP UP T2D population: predicting weight reduction and gastrointestinal tolerability. Short oral discussion (824) – Tuesday 29 September; 13:15–14:15 CEST
  • Post-hoc analysis from SUSTAIN FORTE: Achievement of HbA1c, body weight loss and hypoglycaemia composite endpoints with once-weekly semaglutide 2.0 mg versus 1.0 mg in T2D. Short oral discussion (828) – Tuesday 29 September; 13:15–14:15 CEST
  • SUSTAIN OPTIMIZE CGM: Continuous glucose monitoring outcomes with once-weekly s.c. semaglutide 2.0 mg added to dose-reduced basal insulin vs dose-titrated basal insulin in adults with type 2 diabetes: Oral presentation (14) – Tuesday 29 September; 10:00–11:30 CEST
  • FLOW mediation analysis: Evidence from mediation analysis of 72 pre-specified cardio-kidney-metabolic proteins: Oral presentation (LBA 30) – Thursday 1 October; 15:30–17:00 CEST
  • FLOW trial plasma proteomics: identifies prognostic signatures and pharmacodynamic pathway modulation by semaglutide. Oral presentation (LBA 28) – Thursday 1 October; 15:30–17:00 CEST
  • Semaglutide RWE in China T2D (SPOTLIGHT): Semaglutide reduces the risk of cardiovascular and renal events in Chinese type 2 diabetes patients – a real-world retrospective database study. Short oral discussion (Event A, 733) – Tuesday 29 September; 12:00-13:00
  • SPOTLIGHT primary prevention: Semaglutide reduces cardiovascular event risk in the primary prevention setting among Chinese patients with type 2 diabetes: a real-world retrospective cohort study. Short oral discussion (Event A, LBA 40) – Tuesday 29 September; 12:00-13:00
  • SPOTLIGHT combination therapy: Semaglutide in combination use with SGLT2i reduces cardiovascular events compared to SGLT2i alone use in Chinese patients with type 2 diabetes. Short oral discussion (Event A, LBA 42) – Tuesday 29 September; 12:00-13:00

UBT251 (diabetes and obesity):

  • UBT251 (obesity), a triple hormone receptor agonist in adults with overweight or obesity: a multicenter, double-blind, placebo-controlled, randomized, phase 2 trial. Short oral discussion (Event D, 797) – Wednesday 30 September; 13:00–14:00 CEST
  • UBT251 (diabetes), a triple GLP-1, GIP, and GCG receptor agonist in patients with type 2 diabetes: a multicenter, double-blind, placebo- and active-controlled, randomised, phase II trial. Oral presentation (124) – Wednesday 30 September; 14:30–16:00 CEST

Insulin Icodec

  • ONWARDS 10 CGM-based metrics: Continuous glucose monitoring-based metrics in adults switching to once-weekly icodec without an initial one-time additional dose vs once-daily glargine U100. Post hoc analysis of ONWARDS 10. Short Oral discussion (Event F, 860) – Thursday 1 October; 14:00–15:00 CEST

IcoSema

  • COMBINE 4 BL BMI: Efficacy and hypoglycaemia outcomes with once-weekly IcoSema vs glargine U100 in T2D by baseline BMI: COMBINE 4. Short oral discussion (854) – Thursday 1 October; 12:45–13:45 CEST
  • COMBINE 4 BL HbA1c: Efficacy and hypoglycaemia outcomes with once-weekly IcoSema vs glargine U100 in T2D by baseline HbA1c: COMBINE 4. Short oral discussion (853) – Thursday 1 October; 12:45–13:45 CEST

About semaglutide
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the effects of the naturally occurring hormone GLP-1, which regulates blood sugar and body weight. Semaglutide has been tested in several robust clinical development programmes and outcome studies in cardiometabolic diseases, including type 2 diabetes, obesity, cardiovascular disease, heart failure, chronic kidney disease, liver disease and other related cardiometabolic diseases. Semaglutide is marketed under the brand names Wegovy® (injection or tablet), Ozempic® (injection or tablet) and Rybelsus® (tablet).

About CagriSema
CagriSema is being investigated by Novo as a once-weekly subcutaneous injectable treatment for adults with overweight or obesity (REDEFINE programme) and as a treatment for adults with type 2 diabetes (REIMAGINE programme). CagriSema is a fixed-dose combination of a long-acting amylin analog, cagrilintide and a GLP-1 receptor agonist, semaglutide.

About Fatty liver disease
Fatty liver disease – also known as MASH (metabolic dysfunction-associated steatohepatitis) – is a common condition in which excess fat builds up in the liver. Over time, this can cause inflammation and liver damage, especially in people with obesity, type 2 diabetes or other metabolic health conditions. The disease can range from mild fat buildup to more serious forms that may lead to scarring and reduced liver function.

About zenagamtide
Zenagamtide, formerly known as amycretin, is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo to provide a treatment for adults with overweight or obesity (AMAZE programme) and as a treatment for adults with type 2 diabetes (AMBITION programme). Zenagamtide is under investigation for oral and subcutaneous administration.

About type 2 diabetes
Type 2 diabetes is a chronic condition that affects how the body processes blood sugar (glucose) for energy. 589 million adults (20-79 years) are living with diabetes – 1 in 9. This number is predicted to rise to 853 million by 2050. Diabetes was responsible for 3.4 million deaths in 2024 – 1 every 9 seconds.

About obesity
Obesity is a serious, chronic, progressive, and complex disease that requires long-term management. One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off. Obesity is influenced by a variety of factors, including genetics, social determinants of health and the environment.

Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube. 

Contacts for further information

Novo Nordisk Media:  
Ambre James-Brown
+45 3079 9289
globalmedia@novonordisk.com

Liz Skrbkova (US)
+1 609 917 0632
USMediaRelations@novonordisk.com

Novo Nordisk Investors:  
Michael Novod
+45 3075 6050
nvno@novonordisk.com

Sina Meyer
+45 3079 6656
azey@novonordisk.com

Christoffer Togo Solgaard-Tullin
+45 3079 1471
cftu@novonordisk.com

 
Ida Schaap Melvold
+45 3077 5649
idmg@novonordisk.com

Mads Berner Bruun
+45 3075 2936
mbbz@novonordisk.com

Frederik Taylor Pitter (US)
+1 609 613 0568
fptr@novonordisk.com

Alex Bruce (US)
+1 640 230 0276
axeu@novonordisk.com

Attachment

September 16, 2026
News Release

First Patient In – BioPorto Initiates Patient Enrollment as part of the ProNephro AKI® U.S. Adult Urine NGAL Validation Study.

COPENHAGEN, DENMARK, September 16 , 2026 – BioPorto A/S (“BioPorto” or “Company”) (CPH: BIOPOR) today announced the enrollment of the first patient as part of the ProNephro AKI U.S. Adult Urine NGAL Validation Study, marking an important milestone in the company’s clinical efforts to expand ProNephro AKI (NGAL) to the adult population. The ProNephro AKI U.S. Adult Urine NGAL Validation Study is designed to validate the clinical performance of ProNephro AKI (NGAL) for risk assessment of moderate to severe Acute Kidney Injury (AKI) in adult patients admitted to the Intensive Care Unit (ICU). The study follows BioPorto’s recently completed adult AKI cut-off study and represents the next phase of clinical evaluation for a potential adult indication in the United States.

CEO Carsten Buhl commented: “Today’s first patient enrollment marks another major milestone in BioPorto’s strategy to expand ProNephro AKI into the U.S. adult market. Following the successful completion of the AKI cut-off study, we are now advancing into the validation phase with a study designed to enroll approximately 900 patients across leading U.S. hospitals. Together with ProPharma, our clinical research partner from the preceding study, we are taking the critical steps toward generating the clinical evidence needed to support an adult indication in the United States.”

First patient enrollment for the ProNephro AKIU.S. Adult Urine NGAL Validation Study

The first patient in the ProNephro AKI U.S. Adult Urine NGAL Validation Study has been enrolled at Massachusetts General Hospital. The study is expected to enroll approximately 900 patients across multiple U.S. clinical sites, creating a broad and representative clinical dataset to support the expansion of ProNephro AKI (NGAL) to adult patients.

BioPorto Continues with ProPharma as Clinical Research Organization

BioPorto will continue with ProPharma as the Clinical Research Organization in the study, following its involvement in the preceding AKI cut-off study. ProPharma also assisted BioPorto as the Clinical Research Organization in the ProNephro AKI U.S. Adult Urine NGAL cut-off Study.

ProNephro AKI (NGAL) is currently cleared by the U.S. Food and Drug Administration (FDA) for patients 3 months through 21 years of age. The ProNephro AK U.S. Adult Urine NGAL Validation Study is intended to support BioPorto’s clinical and regulatory pathway toward a potential adult indication in the United States.

To receive BioPorto’s Company Announcements, Press Releases, Newsletters and other business relevant information, please sign up on https://bioporto.com/investor-contact/.

Investor Relations contacts

Klaus Juhl Wulff, BioPorto A/S, investor@bioporto.com, C: +45 25 63 39 90

Forward looking statement disclaimer

Certain statements in this news release are not historical facts and may be forward-looking statements. Forward-looking statements include statements regarding the intent, belief or current expectations with respect to the Company’s expectations, intentions and projections regarding its future performance including the Company’s Guidance for 2026; currency exchange rate fluctuations; anticipated events or trends and other matters that are not historical facts, including with respect to implementation of manufacturing and quality systems, commercialization of NGAL tests, and the development of future products and new indications; concerns that may arise from additional data, analysis or results obtained during clinical trials; and, the Company’s ability to successfully market both new and existing products. These forward-looking statements, which may use words such as “aim”, “anticipate”, “believe”, “intend”, “estimate”, “expect” and words of similar meaning, include all matters that are not historical facts. These forward-looking statements involve risks, and uncertainties that could cause the actual results of operations, financial condition, liquidity, dividend policy and the development of the industry in which the Company’s business operates to differ materially from the impression created by the forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Given these risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of such statements and, except as required by applicable law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Factors that may impact BioPorto’s success are more fully disclosed in BioPorto’s periodic financial filings, including its Annual Report for 2025, particularly under the heading “Risk Factors”.

About BioPorto

BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.

The Company’s flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide.

BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit www.bioporto.com.

SINGAPORE, Sept. 16, 2026 (GLOBE NEWSWIRE) — Valeura Energy Inc. (TSX:VLE, OTCQX:VLERF) (“Valeura” or the “Company”) announces an exploration discovery near its Manora(1) oil field and completion of a successful development and appraisal drilling campaign on its Jasmine field(2), in the Gulf of Thailand.

      (1)   Block G1/48, 70% operated working interest
      (2)   Block B5/27, 100% operated interest

Dr. Sean Guest, President and CEO commented:
“Our discovery of a new accumulation of oil very nearby our Manora field is a game-changer for Block G1/48. The results for net pay encountered exceed our pre-drill estimates and is likely to justify a new satellite facility development on the block. We are now moving into a development planning phase which will also include appraising the proximal Malida oil field. Additionally, the discovery of new and thicker reservoir sands in this structure points to other exploration upside in the vicinity. We expect that the development of this new field, which will be named ‘Suraphi’ will create a new lease on life for the greater Manora field area, by utilising the existing Manora-A processing facility for more oil than the Manora field alone.

Separately, we have also completed a successful development and appraisal programme on our Jasmine field, where we continue to add producible volumes and identify new opportunities for further organic development.

I am very pleased to see our drilling programme continue delivering value through all facets of operations – development, appraisal, and exploration. With these successes, we are facing an expanded set of organic investment opportunities, while at the same time continuing to pursue aggressively, our inorganic growth ambitions.”

Suraphi Oil Discovery
Valeura discovered the Suraphi field by drilling the Manora-9 open water exploration well and associated sidetracks, approximately 4.5 km to the northeast of its Manora A platform. Several prospects were targeted in the operation, each within a distinct fault block. The E prospect identified several oil-bearing sandstone intervals within the 600-series lacustrine sands, and intersected oil over a gross column measuring 626 ft (162 ft net oil pay). The D prospect encountered a similar oil-bearing reservoir section in the adjacent fault block, within a gross column measuring 849 ft (172 ft net oil pay). A third sidetrack tested a shallower and riskier play which was not hydrocarbon-bearing. However, success in the D and E fault blocks has effectively de-risked a third adjacent fault block (F), which is well-imaged on 3D seismic.

Based on the Company’s mapping, as calibrated by pressure data collected during drilling, there is evidence to suggest that all three fault blocks could be filled to their spill point, thereby constituting a ‘best case scenario’ discovery within these prospects. The Company estimates that even when measured more conservatively, by only considering the deepest oil demonstrated in the wells, the discovery would likely still justify a satellite facility development on the block.  

Valeura believes an additional satellite platform to develop the Suraphi field also creates an opportunity to develop the otherwise-stranded Malida field, 3.5 km to the east. In addition, as this oil discovery has encountered a thicker than expected reservoir interval and has demonstrated oil migration into the area, it derisks a number of nearby exploration prospects, thereby adding to the total potential magnitude of this discovery.

This theme is consistent with the characteristics of the Company’s other fields in the Gulf of Thailand, all which have exceeded their original oil recovery expectations through ongoing exploration, appraisal, and development. In addition, by creating a satellite facility tied in to the Manora wellhead and processing platform, Valeura anticipates an extension to the productive life of the Manora field, thereby adding tail oil production which would otherwise be considered uneconomic and not produced.

Valeura is moving immediately into a development planning phase, to establish a plan to maximise the value of the discovery, and to provide scope for future development in the vicinity. Concurrently, the Company will conduct studies to plan for appraisal of the Malida field and to re-evaluate the nearby exploration prospects for inclusion in future drilling campaigns.

Jasmine Development and Appraisal Drilling Success
Prior to the Manora-9 well, Valeura completed a successful development and appraisal drilling campaign on its Jasmine field. A total of four successful wellbores were completed, two on the Jasmine-C platform and two on Jasmine-D. This includes two horizontal development wells and two dual-objective deviated wells drilled for both development and appraisal targets. Both of the multi-objective wells successfully appraised several new zones, which will now be studied as potential future development candidates.

As a result of this drilling campaign, the Company has recorded a net increase in the amount of organic investment opportunities at Jasmine. In addition, the immediate impact has been an up-tick in oil production, offsetting the near-term impact of natural production declines. Oil production rates have increased from approximately 7,570 bbls/d (before royalties) in the seven-day period before the new wells were brought onstream, to rates in the seven-day period after bringing all wells onstream of approximately 8,250 bbls/d (before royalties).

Further Drilling
Valeura will shortly demobilise the Borr Mist drilling rig and subsequently release it from its contract. The Company intends to resume Gulf of Thailand drilling operations in early November 2026, when it begins its charter of the Shelf Drilling Enterprise rig to initially conduct a drilling programme on its Nong Yao field (Block G11/48, 90% operated working interest), followed by development drilling on the Wassana field (Block G10/48, 100% interest).

For further information, please contact:

Valeura Energy Inc. (General Corporate Enquiries)                +65 6373 6940
Sean Guest, President and CEO
Yacine Ben-Meriem, CFO
Contact@valeuraenergy.com  

Valeura Energy Inc. (Investor and Media Enquiries)                +1 403 975 6752
Robin James Martin, SVP, Communications and Investor Relations
IR@valeuraenergy.com

Contact details for the Company’s advisors, covering research analysts and joint brokers, including Auctus Advisors LLP, Beacon Securities Limited, Canaccord Genuity Ltd (UK), Cormark Securities Inc., Research Capital Corporation, Roth Canada Inc., and Stifel Nicolaus Europe Limited, are listed on the Company’s website at www.valeuraenergy.com/investor-information/analysts/.

About the Company

Valeura Energy Inc. is a Canadian public company engaged in the exploration, development and production of petroleum and natural gas in Thailand and Türkiye. The Company is executing a growth-oriented strategy, reinvesting into its producing asset portfolio while deploying capital toward further organic and inorganic growth across Southeast Asia. Valeura is committed to delivering value-accretive growth for all stakeholders, underpinned by high standards of environmental, social and governance responsibility.

Additional information relating to Valeura is also available on SEDAR+ at www.sedarplus.ca.

Advisory and Caution Regarding Forward-Looking Information

Certain information included in this news release constitutes forward-looking information under applicable securities legislation. Such forward-looking information is for the purpose of explaining management’s current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes, such as making investment decisions. Forward-looking information typically contains statements with words such as “anticipate”, “believe”, “expect”, “plan”, “intend”, “estimate”, “propose”, “project”, “target” or similar words suggesting future outcomes or statements regarding an outlook. Forward-looking information in this news release includes, but is not limited to: the discovered volumes being sufficient to justify a satellite facility development; plans for future drilling, including appraisal of the Malida oil field; the potential for other upside exploration in the vicinity; the potential for success at the Jasmine field to add producible volumes and to identify new opportunities; estimates for the amount of oil pay encountered in the E and D prospects; success in the D and E fault blocks resulting in a de-risking of the F fault block; the three fault blocks being filled to their spill point; the potential for a Suraphi field development to create an opportunity for development of the Malida field; the potential for an extension to the productive life of the Manora field; and timing to resume drilling operations, and the composition of its forward drilling campaign.

Forward-looking information is based on management’s current expectations and assumptions regarding, among other things: political stability of the areas in which the Company is operating; continued safety of operations and ability to proceed in a timely manner; continued operations of and approvals forthcoming from governments and regulators in a manner consistent with past conduct; future drilling activity on the required/expected timelines; the prospectivity of the Company’s lands; the continued favourable pricing and operating netbacks across its business; future production rates and associated operating netbacks and cash flow; decline rates; future sources of funding; future economic conditions; the impact of inflation of future costs; future currency exchange rates; interest rates; the ability to meet drilling deadlines and fulfil commitments under licences and leases; future commodity prices; the impact of the ongoing conflicts between the U.S.-Israel and Iran, and between Russia and Ukraine; royalty rates and taxes; future capital and other expenditures; the success obtained in drilling new wells and working over existing wellbores; the performance of wells and facilities; the availability of the required capital to funds its exploration, development and other operations, and the ability of the Company to meet its commitments and financial obligations; the ability of the Company to secure adequate processing, transportation, fractionation and storage capacity on acceptable terms; the capacity and reliability of facilities; the application of regulatory requirements respecting abandonment and reclamation; the recoverability of the Company’s reserves and contingent resources; future growth; the sufficiency of budgeted capital expenditures in carrying out planned activities; the impact of increasing competition; the ability to efficiently integrate assets and employees acquired through acquisitions; global energy policies going forward; future debt levels; and the Company’s continued ability to obtain and retain qualified staff and equipment in a timely and cost efficient manner. In addition, the Company’s work programmes and budgets are in part based upon expected agreement among joint venture partners and associated exploration, development and marketing plans and anticipated costs and sales prices, which are subject to change based on, among other things, the actual results of drilling and related activity, availability of drilling, offshore storage and offloading facilities and other specialised oilfield equipment and service providers, changes in partners’ plans and unexpected delays and changes in market conditions. Although the Company believes the expectations and assumptions reflected in such forward-looking information are reasonable, they may prove to be incorrect.

Forward-looking information involves significant known and unknown risks and uncertainties. Exploration, appraisal, and development of oil and natural gas reserves and resources are speculative activities and involve a degree of risk. A number of factors could cause actual results to differ materially from those anticipated by the Company including, but not limited to: the ability of management to execute its business plan or realise anticipated benefits from acquisitions; the risk of disruptions from public health emergencies and/or pandemics; competition for specialised equipment and human resources; the Company’s ability to manage growth; the Company’s ability to manage the costs related to inflation; disruption in supply chains; the risk of currency fluctuations; changes in interest rates, oil and gas prices and netbacks; potential changes in joint venture partner strategies and participation in work programmes; uncertainty regarding the contemplated timelines and costs for work programme execution; the risks of disruption to operations and access to worksites; potential changes in laws and regulations, the uncertainty regarding government and other approvals; counterparty risk; the risk that financing may not be available; risks associated with weather delays and natural disasters; and the risk associated with international activity. See the Company’s most recent annual information form and the MD&A for a detailed discussion of the risk factors.

The forward-looking information contained in this new release is made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, unless required by applicable securities laws. The forward-looking information contained in this new release is expressly qualified by this cautionary statement.

This news release does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction, including where such offer would be unlawful. This news release is not for distribution or release, directly or indirectly, in or into the United States, Ireland, the Republic of South Africa or Japan or any other jurisdiction in which its publication or distribution would be unlawful.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this news release.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

The board of the state-owned company UAB “Valstybės investicinis kapitalas” (legal entity code 305611945) has decided to approve the increase in the authorized capital of UAB “EPSO-G Invest”. UAB “Valstybinis investicinis kapitalas” has owned 49 percent of the shares of UAB “EPSO-G Invest”. UAB “EPSO-G Invest” legal entity code 306949519 authorized capital is increased by EUR 3,360,600 from EUR 7,405,600 to EUR 10,765,600, by issuing 3 360 000 ordinary registered intangible shares of UAB “EPSO-G Invest” with a nominal value of EUR 1.

The issue price of one newly issued share is EUR 10. The total issue price of the newly issued share issue of EPSO-G Invest is equal to EUR 33,600,000. The difference between the issue price and the nominal value of the newly issued EPSO-G Invest shares, amounting to EUR 30,240,000, shall be credited to the share premium.

The authorized capital of UAB EPSO-G Invest is increased by issuing and distributing 3,360,000 new ordinary registered shares to the shareholders according to the following procedure and portions:

  1. EPSO-G: 1,713,600 shares, with a total issue price of EUR 17,136,000, consisting of the total nominal value of these shares equal to EUR 1,713,600 and a share premium of EUR 15,422,400;
  2. UAB Valstybės investicinis kapitalas: 1,646,400 shares, with a total issue price of EUR 16,464,000, consisting of the total nominal value of these shares equal to EUR 1,646,400 and a share premium of EUR 14,817,600.

Contact person:

Vaidas Daktariunas
Valstybės investicinis kapitalas UAB, Chief Executive Officer
Phone: +370 656 03356
E-mail: info@vika.lt

Press contact:
Sereydana Oum
Tel.: + 33 6 61 42 03 59
E-mail: sereydana.oum@capgemini.com

Businesses accelerate their climate adaptation investments
yet just 15% have fully quantified the financial impact of climate-related risks

  • Nearly 7 in 10 executives are prioritizing climate adaptation to boost business resilience
  • Share of organizations falling behind on net zero goals up to 11% in 2026, from 1% in 2025
  • Access to critical resources is becoming a stronger driver of sustainability decisions than emissions-reduction targets for more than 7 in 10 organizations

Paris, September 16, 2026 – Climate disruption, water stress, resource constraints, and geopolitical volatility are increasing pressure on business operations, supply chains and growth. According to the fifth edition of the Capgemini Research Institute’s A World in Balance: The resilience reset report, organizations are responding by placing greater emphasis on climate adaptation and business resilience1. In addition, nearly two-thirds of organizations say they use AI to advance their sustainability agenda. However, the research also reveals a widening gap between ambition and delivery, as more organizations fall behind on net zero commitments and struggle to measure climate- and AI-related impacts.

Sustainability strategies increasingly focus on resilience, business continuity, and access to critical resources
Nearly nine in 10 organizations report that climate-related events have disrupted their supply chains. In response, 68% of executives say their organization actively prioritizes climate adaptation, up from 56% in 2025. The way business leaders perceive sustainability is evolving, stretching beyond reporting and compliance and increasingly being seen through the lens of measurable business outcomes, resilience, continuity, and access to critical resources. Nearly two-thirds of executives identify energy- and critical-resource security as a key driver of sustainability investment. More than seven in 10 say that securing access to critical resources – including energy, water, and materials – now has greater influence on sustainability decision-making than emissions-reduction targets.

This transition is also reshaping organizations’ strategic priorities, with more than three-quarters of executives saying their organization is accelerating efforts to integrate energy and resource resilience into business and sustainability strategies. Alongside energy security, water-related risks are a growing concern – 61% of executives believe water scarcity will present a greater constraint on business growth than energy availability over the next five years.

While awareness of these risks is growing, operational readiness remains inconsistent. Just 15% of organizations have fully quantified the financial impact of climate-related disruptions, with just over one in four executives say their organization has assessed climate risks across its extended value chain or deployed climate-risk analytics tools or platforms. Nevertheless, there are signs that adaptation capabilities are maturing – the share of executives who say their organization is underprepared for climate impacts has fallen from 54% in 2025 to 44% in 2026.

“Climate change disruptions have become our new normal, and yet there is still a wide gap between business leaders’ awareness of the risks and actual implementation. In order to protect their supply chains, operations, infrastructure, and access to essential energy, water, and materials, they can no longer defer climate action,” said Cyril Garcia, Global head of Sustainability services and Corporate Responsibility, and Member of the Group Executive Board at Capgemini. “It is encouraging to see organizations prioritize adaptation and resilience for sustainable growth. But as climate and political risks evolve, organizations must continue to embed sustainability into their core business strategy and day-to-day operations.”

Sustainability investments continue to demonstrate a positive ROI
Nearly seven in 10 organizations say their sustainability initiatives have generated a net-positive return on investment. Almost two-thirds of executives (64%) say sustainability investments have boosted sales, up from 47% in 2025, and 74% acknowledge that sustainable practices have enhanced their brand equity.

Looking ahead, 83% say their organization will increase climate adaptation spending over the next 12-18 months, reflecting a trend that is already visible today: organizations spent 1.04% of revenue on sustainability initiatives last year, exceeding the 0.8% they initially allocated. This investment is also helping organizations manage business disruption, as nearly two-thirds of executives from manufacturing or asset-intensive sectors say these investments have improved operational efficiency under supply constraints, while slightly over half say they have enhanced their ability to anticipate and respond to operational and supply-chain disruptions.

Businesses struggle to follow through with their net zero commitments
While most organizations have sustainability goals, the research suggests that implementation remains challenging. In 2026, 84% of organizations say they have set science-based targets, up three points since 2025. Yet only 42% say they are on track to meet their 2030 or interim targets. The execution gap is particularly visible in net zero programs. The number of organizations falling behind on their net zero goals has increased more than tenfold since last year. Moreover, 29% say they have postponed their net zero objectives, compared with just 8% last year.

Nearly two-thirds of organizations acknowledge that aligning sustainability efforts with science-based targets is challenging. Data availability, measurement, and value-chain visibility remain challenging. The proportion of organizations able to measure and collect data across all Scope 3 emissions has fallen to 34%, from 54% in 2025, underscoring the difficulty of tracking and managing emissions beyond direct operations.

AI supports sustainability initiatives, but environmental impact is hard to measure
AI is also increasingly considered as a tool to help turn sustainability ambition into action. Nearly two-thirds of organizations say they use AI to advance their sustainability agenda, and more than a third use or plan to use agentic AI for sustainability initiatives. At the same time, the environmental implications of AI are increasingly being recognized at senior levels. Seven in 10 organizations say AI’s sustainability implications are discussed in the boardroom.

However, oversight and disclosure of the technology remain limited. Nearly half of executives say AI has significantly increased greenhouse gas emissions. Yet concern about AI’s environmental impact appears to be outpacing organizations’ ability to measure it: just over a third of executives say their organization measures the energy consumption of AI systems and workloads, and the associated carbon footprint.

To access the full report: https://www.capgemini.com/insights/research-library/sustainability-trends-2026/

Methodology of the report
The Capgemini Research Institute surveyed 2,100 executives employed at 701 organizations, each with more than $1 billion in annual revenue, across 13 countries in North America, Europe, and Asia-Pacific and in 12 industries and sectors. Respondents represented industries and sectors covered across: aerospace and defense, agriculture and forestry, automotive, consumer products, energy, financial services, healthcare and life sciences, industrial manufacturing, retail, telecom, utilities, and the public sector/government. The survey took place in June and July 2026. The research also includes a global survey of 6,500 consumers and interviews with 15 executives at leading organizations.

About Capgemini
Capgemini is the business transformation partner for enterprises in the age of AI. We help organizations imagine and build an intelligent, sustainable future, combining AI, technology and human ingenuity to transform how they operate, innovate and grow. With unique end-to-end capabilities spanning strategy, technology, engineering and intelligent operations, we bring together deep industry expertise and market-leading capabilities in AI, cloud and data to turn ambition into measurable business outcomes at scale. Supported by a robust ecosystem of partners and nearly 60 years of expertise, Capgemini is a responsible and diverse global organization of over 410,000 team members in more than 50 countries. The Group reported 2025 revenues of €22.5 billion.

Make it real | www.capgemini.com

About the Capgemini Research Institute
The Capgemini Research Institute is Capgemini’s in-house think-tank on all things digital. The Institute publishes research on the impact of digital technologies on large traditional businesses. The team draws on the worldwide network of Capgemini experts and works closely with academic and technology partners. The Institute has dedicated research centers in India, Singapore, the United Kingdom and the United States. It was ranked #1 in the world for the quality of its research by independent analysts for six consecutive times – an industry first.

Visit us at https://www.capgemini.com/researchinstitute/


1 Resilience refers here to an organization’s ability to anticipate, adapt to, and withstand disruptions across its operations, supply chains, resources, and markets.

Attachment

Kalmar and ICTSI continue collaboration with hybrid straddle carrier order

Kalmar has concluded an agreement with International Container Terminal Services, Inc. (ICTSI) to supply a total of 12 Kalmar hybrid straddle carriers.
Kalmar has concluded an agreement with International Container Terminal Services, Inc. (ICTSI) to supply a total of 12 Kalmar hybrid straddle carriers.

KALMAR CORPORATION, PRESS RELEASE, 16 SEPTEMBER 2026 AT 9.00 (EEST)

Kalmar and ICTSI continue collaboration with hybrid straddle carrier order for new South Luzon Container Terminal

Kalmar has concluded an agreement with International Container Terminal Services, Inc. (ICTSI) to supply a total of 12 Kalmar hybrid straddle carriers. The machines will be deployed at the South Luzon Container Terminal (SLCT), located within Bauan International Port in Batangas, the Philippines. The significant order, which also includes MyKalmar INSIGHT coverage for all machines, was booked in Kalmar’s Q3 2026 order intake, with delivery of all machines scheduled to be completed during Q3 2027.

ICTSI is one of the largest and most successful container terminal operators in the Philippines and a world leader in providing container handling, storage and related services to shipping lines and cargo owners. 

The South Luzon Container Terminal (SLCT) is located approximately 110 kilometers south of Manila, within the Bauan International Port in Batangas, and will support industrial and manufacturing activities. Once completed, SLCT will have an 800‑metre quay, 38 hectares of yard and an annual capacity of 1.6 million TEU.

As part of the agreement, Kalmar will also supply a straddle carrier simulator. The simulator will be located at the terminal and will be used to train new operators and in the future enable existing operators to refresh their skills.

Arthur de Jonge, Senior Director Projects and Systems ICTSI: “The SLCT project represents a significant investment for our organisation and demonstrates what can be achieved through long-term collaboration and commitment. As a long-term partner, Kalmar can offer the proven technology and unparalleled service and fleet management expertise that a project of this nature demands. We are very pleased to be able to continue our collaboration.”

Daniel Ho, Vice President, GTO Key Account Management, Kalmar: “Kalmar and ICTSI have a long and distinguished history of close collaboration at a number of terminals around the world. We are proud to be able to deliver the very first Kalmar straddle carriers to a terminal in the Philippines and grateful for the trust the ICTSI have placed in our proven hybrid technology.” 

Further information for the press:

Daniel Ho, Vice President, GTO Key Account Management, Kalmar, tel.+65 9746 7375 daniel.ho@kalmarglobal.com

Annelies Nentjes, Director Marketing and Communications Horizontal Transportation, Kalmar, tel. +31 6 1323 98 46, annelies.nentjes@kalmarglobal.com  

Kalmar (Nasdaq Helsinki: KALMAR) is moving goods in critical supply chains around the world, with the vision to be the forerunner in sustainable material handling equipment and services. The company offers a wide range of industry shaping heavy material handling equipment and services to ports and terminals, distribution centres, manufacturing and heavy logistics. Headquartered in Helsinki, Finland, Kalmar operates globally in over 120 countries and employs approximately 5,300 people. In 2025, the company’s sales totalled approximately EUR 1.7 billion. www.kalmarglobal.com 

Attachment

THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS

Neuberger Private Equity Partners Announces Transaction in Own Shares

St Peter Port, Guernsey 16 September 2026

Neuberger Private Equity Partners Limited (“NBPE” or the “Company”) today announces details of Class A Shares bought back pursuant to general authority granted by shareholders of the Company on 11 June 2026 and the share buy-back agreement with Jefferies International Limited.

Transaction on London Stock Exchange

Date of purchase of Shares

15 September 2026
Number of Shares purchased

39,142 Class A Shares
Highest price/lowest price paid

£14.50 / £14.32
ISIN for the Shares GG00B1ZBD492

All Class A Shares bought back will be cancelled. Following the cancellation, the number of outstanding Class A Shares is 38,692,560‬. The Company also has 3,150,408 Class A shares held in treasury. For reporting purposes under the FCA’s Disclosure Guidance and Transparency Rules the market should use the figure of 38,692,560 voting rights when determining if they are required to notify their interest in, or a change to their interest in the Company.

For further information, please contact:

NBPE Investor Relations        +44 20 3214 9002
Luke Mason        NBPrivateMarketsIR@nb.com

Oak Group        +44 1481 723450

        NBPEP@oak.group

About Neuberger Private Equity Partners Limited

NBPE invests in direct private equity investments alongside market leading private equity firms globally. NB Alternatives Advisers LLC (the “Investment Manager”), an indirect wholly owned subsidiary of Neuberger Berman Group LLC, is responsible for sourcing, execution and management of NBPE. The vast majority of direct investments are made with no management fee / no carried interest payable to third-party GPs, offering greater fee efficiency than other listed private equity companies. NBPE seeks capital appreciation through growth in net asset value over time while paying a bi-annual dividend.

LEI number: 213800UJH93NH8IOFQ77

About Neuberger
Neuberger is an employee-owned, private, independent investment manager founded in 1939 with approximately 3,000 employees across 26 countries. The firm manages $567 billion of equities, fixed income, private markets, real estate and hedge fund portfolios for global institutions, advisors and individuals. Neuberger’s investment philosophy is founded on active management, fundamental research and engaged ownership. The firm is proud to be recognized for its commitment to its two constituents, clients and employees. Again this past year, we were named Best Asset Manager for Institutional Investors in the US (Crisil Coalition Greenwich) and the #1 Best Place to Work in Money Management (Pensions & Investments, firms with more than 1,000 employees). Neuberger has no corporate parent or unaffiliated external shareholders. Visit www.nb.com for more information, including www.nb.com/disclosure-global-communications for information on awards.
Data as of March 31, 2026.

Media Contacts:
US: Soogyung Jordan: Soogyung.Jordan@nb.com
EMEA: Fiona Kehily: Fiona.Kehily@nb.com

All Neuberger figures are as of March 31, 2026, unless otherwise noted, and are subject to change without notice. The firm data, including employees and assets under management, reflect the collective data of the various affiliated investment advisors who are subsidiaries of Neuberger Berman Group LLC. The company history/timeline includes the history of all the company’s subsidiaries, including predecessor companies and acquisitions.

This material is issued on a limited basis through various global subsidiaries and affiliates of Neuberger Berman Group LLC. Please visit www.nb.com/disclosure-global-communications to learn about each company and the legal restrictions and restrictions. The name “Neuberger Berman” and logo are registered service marks of Neuberger Berman Group LLC.

© 2026 Neuberger Berman Group LLC. All rights reserved.

This press release appears as a matter of record only and does not constitute an offer to sell or a solicitation of an offer to purchase any security.

NBPE is established as a closed-end investment company domiciled in Guernsey. NBPE has received the necessary consent of the Guernsey Financial Services Commission. The value of investments may fluctuate. Results achieved in the past are no guarantee of future results. This document is not intended to constitute legal, tax or accounting advice or investment recommendations. Prospective investors are advised to seek expert legal, financial, tax and other professional advice before making any investment decision. Statements contained in this document that are not historical facts are based on current expectations, estimates, projections, opinions and beliefs of NBPE’s investment manager. Such statements involve known and unknown risks, uncertainties and other factors, and undue reliance should not be placed thereon. Additionally, this document contains “forward-looking statements.” Actual events or results or the actual performance of NBPE may differ materially from those reflected or contemplated in such targets or forward-looking statements.

TME PHARMA CEO MESSAGE

Berlin, Germany, September 16, 2026, 8.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for brain cancer and eye diseases, today publishes a message from its CEO for the shareholders.

Dear Shareholders,
As I look back on the recent period, one clear feeling dominates: remained confidence in the path we are taking. We fully understand that many of you are eager to see concrete decisions. When reaching a decisive phase, waiting can naturally feel long. However, as you know, thorough negotiations and strategic choices do not happen overnight.        
As we move through a pivotal phase for TME Pharma, I would like to share an update on our strategic approach, our financial discipline, and our commitment to long-term value creation.
Our focus remains squarely on securing an outcome that properly reflects the significant potential of our lead asset, NOX-A12.

Executive Alignment & Capital Discipline
My management philosophy across the entities I lead is rooted in absolute alignment with long-term shareholders. We strictly control overhead, and my personal compensation framework is structured to lower cash consumption and to emphasize long-term upside tied directly to company performance and share price appreciation. Furthermore, through direct personal investments and capital contributions, my priority has consistently been to protect existing shareholders from unnecessary dilution wherever possible.

Since June 2025, our disciplined cost-reduction strategy has proven essential. By streamlining our burn rate, we successfully extended our financial runway into the second quarter of 2027. Through the use of standard bond financing, we have maintained a very limited level of dilution since December 2024. This deliberate approach was executed to ensure that TME Pharma retained the independence and time needed to negotiate from a position of strength.

Capitalizing on Market Dynamics
Our capital management strategy was designed to ensure the company was well-positioned as biotech sector sentiment and deal-making dynamics improved. We are observing increasingly positive momentum in the industry, marked by renewed capital flows and strategic demand for clinical-stage assets. TME Pharma is structured to leverage these favorable market conditions for the benefit of our shareholders.

Ongoing Strategic Partnering for NOX-A12
Following our announcement on August 24, 2026, we are continuing our evaluation process. In our discussions with potential partners, our primary focus is to safeguard long-term success. This entails ensuring that the upcoming Phase 2 GLORIA trial is effectively executed under a robust regulatory strategy. In addition, we focus on securing favorable financial terms for our shareholders; a licensing agreement must generate value for shareholders throughout the process so that, in the event of a successful market launch of NOX-A12, we can ultimately benefit from a substantial percentage of peak sales capacity.        
We are working diligently to conclude this final assessment phase and look forward to updating the market as soon as a definitive decision has been reached and formal agreements are finalized.

Future additional activities        
In addition to our developments with our biotech assets, among which NOX-E36 remains a promising asset, I will continue to apply my knowledge and expertise as an investor to create value for TME Pharma shareholders in other areas as well. TME Pharma is a holding company, making it ideally suited to expand its activities and assets.        
We believe that communication with our shareholders is important, but since we only present financial reports on a semi-annual basis, we will choose, if there is enough to report, to keep you informed of developments more frequently through this channel.

Thank you for your continued support and shared vision as we execute these critical strategic milestones.

Sincerely,

Diede van den Ouden
Chief Executive Officer, TME Pharma N.V.

For more information, please contact:
TME Pharma N.V.
Diede van den Ouden, CEO
ir@tmepharma.com
www.tmepharma.com

About TME Pharma

TME Pharma is a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases. The Company’s lead compounds have been designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair.        
TME Pharma has currently 2 main assets for development:

  • NOX-A12 (olaptesed pegol, an anti-CXCL12 L-RNA aptamer), which is being studied (GLORIA Phase 1/2 clinical trial) in newly-diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy. The US FDA and the German BfArM have approved the design of a randomized Phase 2 trial in glioblastoma, and TME Pharma was awarded Fast Track Designation by the FDA for NOX-A12 in combination with radiotherapy and bevacizumab for use in the treatment of the aggressive adult brain cancer, glioblastoma. NOX-A12 in combination with radiotherapy had also previously received orphan drug designation (ODD) for glioblastoma in the United States and glioma in Europe.
  • NOX-E36 (emapticap pegol, L-RNA aptamer inhibiting CCL2 and related chemokines), which is being evaluated in ophthalmic diseases with a high need for well-tolerated therapies with anti-fibrotic effect.

The Company is currently seeking opportunities to secure the financial resources to unlock the value of NOX-A12 and NOX-E36. These steps include:

  • Raising funds from alternative sources
  • Pursuing stable, cash-generating business opportunities to achieve positive operational cash flow for the Company
  • Leveraging tax loss carry forwards

Further information can be found at: www.tmepharma.com.

About the GLORIA Study

The GLORIA (NCT04121455) ‘ready to go’-study is TME Pharma’s dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy).

About the OPTIMUS Study

OPTIMUS (NCT04901741) is TME Pharma’s planned open-label two-arm Phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients.

Disclaimer

Translations of any press release into languages other than English are intended solely as a convenience to the non-English-reading audience. The company has attempted to provide an accurate translation of the original text in English, but due to the nuances in translating into another language, slight differences may exist. This press release includes certain disclosures that contain “forward-looking statements.” Forward-looking statements are based on TME Pharma’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials and the timing of and TME Pharma’s ability to obtain regulatory approvals for NOX-A12 as well as any other drug candidates. Forward-looking statements contained in this announcement are made as of this date, and TME Pharma undertakes no duty to update such information except as required under applicable law.

Attachment

The First and Only Anti-Amyloid Treatment in Japan that Enable At-Home Administration for Alzheimer’s Disease, a Progressive Disease

TOKYO and CAMBRIDGE, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) — Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced today that “LEQEMBI® Pen”, the subcutaneous (SC) formulation of the anti-amyloid beta (Aβ) protofibril antibody “LEQEMBI®” (brand name, generic name: lecanemab) has been approved in Japan as a new route of administration.

LEQEMBI Pen is an autoinjector formulation that enables administration by a care partner or patient self-administration, with two pens (totaling 500 mg) administered once weekly. With this approval, LEQEMBI treatment now offers a new option of once-weekly SC administration at home*, in addition to intravenous (IV) administration every two weeks in a hospital setting.

LEQEMBI Pen may reduce the time required for anti-amyloid therapy administration compared with IV infusions (approximate injection time of 15 seconds per injection). In addition, at-home administration may reduce the burden of clinic visits for patients and their care partners and provide greater flexibility in treatment, allowing patients to make treatment choices that better fit their lifestyles, including fewer constraints on going out and traveling. The improved convenience and flexibility of treatment with LEQEMBI is expected to lower barriers to initiating and continuing treatment with LEQEMBI. Furthermore, LEQEMBI Pen also has the potential to reduce healthcare resources associated with IV dosing, such as nurse monitoring, as well as maintaining infusion capacity. These features are expected to contribute to further streamlining the overall Alzheimer’s disease (AD) treatment pathway. For amyloid-related imaging abnormalities (ARIA) monitoring, as with IV administration, brain magnetic resonance imaging (MRI) is performed prior to initiating treatment and at specified time points after treatment initiation.

AD is a progressive, relentless disease with Aβ and tau as hallmarks that is caused by a continuous underlying neurotoxic process driven by protofibrils that begins before amyloid plaque accumulation and continues after plaque removal.1,2,3 Only LEQEMBI fights AD in two ways – targeting both protofibrils and amyloid plaque.

This marks the third country globally to approve LEQEMBI SC formulation. This approval is based on the integrated results of data and associated modeling and simulation from the 18-month core study of the Phase 3 Clarity AD study of LEQEMBI in patients with mild cognitive impairment (MCI) due to AD or mild AD dementia (collectively referred to as early AD), as well as multiple SC administration sub-studies in its subsequent long-term extension study (LTE). Once-weekly administration of SC formulation 500 mg demonstrated similar exposure to IV administration once every two weeks and supported the expectation that the SC formulation provides efficacy comparable to that of the IV formulation. The overall safety profile of SC administration was generally similar to that of IV administration, while systemic injection/infusion-related reactions were observed less frequently with SC administration (1.4%)** than with IV administration.

Eisai serves as the lead for lecanemab’s development and regulatory submissions globally, with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

* At-home, self-administration using LEQEMBI Pen will be possible after it is listed in the injectable drug list designated by the Minister of Health, Labour and Welfare that health insurance doctor can administer (or prescribe), following deliberation and approval by the Central Social Insurance Medical Council, in principle within 60 days after approval. In addition, the following points are stipulated to be observed when self-administering.

  • When initiating administration, treatment must be administered by a physician or under the direct supervision of a physician at a medical facility.
  • With regard to the applicability of self-administration, the appropriateness thereof shall be carefully considered, and only after providing thorough education and training, and confirming that the patient or family member/caregiver understands the risks associated with administration of this drug and how to respond to them, and that the patient or family member/caregiver is able to reliably administer it themselves, shall self-administration be implemented under the management and guidance of a physician.

** Incidence in participants newly initiated on lecanemab treatment via SC administration, based on clinical data obtained from once-weekly subcutaneous administration of lecanemab 720 mg using vial formulations.

Eisai Co., Ltd.
Public Relations Department
TEL: +81 (0)3-3817-5120

Eisai Europe, Ltd.
EMEA Communications Department
+44 (0) 7760 619251
Emea-comms@eisai.net

Eisai Inc. (U.S.)
Libby Holman
+1-201-753-1945
Libby_Holman@Eisai.com

Biogen Inc.
Madeleine Shin 
+1-781-464-3260
public.affairs@biogen.com
INVESTOR CONTACTS  
   
Eisai Co., Ltd.
Investor Relations Department
TEL: +81 (0) 3-3817-5122
Biogen Inc.
Tim Power
+ 1-781-464-2442
IR@biogen.com
   

Notes to Editors

  1. Product Outline
    1) Product name
        LEQEMBI® Pen
    2) Generic name
        Lecanemab (recombinant)
    3) Indication for use
        Slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease.
    4) Dosage and administration
        The usual dose of lecanemab (recombinant) is 500 mg injected subcutaneously once weekly.
  2. About lecanemab (generic name, brand name: LEQEMBI®)
    Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).

    Lecanemab has been approved in 53 countries and regions including Japan, the U.S., China, Canada, Europe, South Korea, Taiwan, and Saudi Arabia, and is under regulatory review in 6 countries. In September 2023, Eisai received approval in Japan for lecanemab as a treatment for slowing progression of mild cognitive impairment (MCI) and mild dementia due to AD. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks is approved in 9 countries and regions including the U.S., China, the UK, and others, and applications have been filed in 11 countries and regions. The U.S. FDA approved Eisai’s Biologics License Application (BLA) for subcutaneous maintenance dosing (360 mg) with LEQEMBI IQLIK in August 2025. For subcutaneous initiation treatment (500 mg), approval was obtained in the U.S. in July 2026 and China in September 2026, and applications are under review in 2 countries.

    Since July 2020, the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer’s Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.

  3. About Protofibrils 
    Protofibrils are thought to be the most toxic Aβ species that contribute to brain damage in AD and play a major role in the cognitive decline of this progressive and devastating disease. Protofibrils can cause neuronal and synaptic damage in the brain, which can subsequently adversely affect cognitive function through multiple mechanisms. The mechanism by which this occurs has been reported not only by increasing the formation of insoluble Aβ plaques, but also by directly damaging signaling between neurons and other cells. It is believed that reducing protofibrils may reduce neuronal damage and cognitive impairment, potentially preventing the progression of AD.2

  4. About the Collaboration between Eisai and Biogen for AD
    Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.
  5. About the Collaboration between Eisai and BioArctic for AD
    Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.
  6. About Eisai Co., Ltd.
    Eisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.

    In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.

    For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe. For audiences based in the UK and Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.

  7. About Biogen
    Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

    The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTube.

    Biogen Safe Harbor
    This news release contains forward-looking statements, including those about the potential clinical effects of LEQEMBI (lecanemab); the potential benefits, safety and efficacy of LEQEMBI; the potential for LEQEMBI Pen to increase flexibility in treatment options and reduce use of healthcare resources and the time required for and burden of clinical visits; potential regulatory discussions, submissions and approvals and the timing thereof; the treatment of Alzheimer’s disease; the anticipated benefits and potential of Biogen’s collaboration arrangements with Eisai; the potential of Biogen’s commercial business and pipeline programs, including lecanemab; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements.

    These forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our corporate strategy; the successful execution of our strategic and growth initiatives, including acquisitions; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission.

    These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned “Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.

    Digital Media Disclosure
    From time to time, we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account (https://x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and these social media channels in addition to our press releases, SEC filings, public conference calls and websites, as the information posted on them could be material to investors.

References

  1. Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z
  2. Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer’s Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.
  3. Hampel H, Hardy J, Blennow K, et al. The amyloid pathway in Alzheimer’s disease. Mol Psychiatry. 2021;26(10):5481-5503.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.